Lazcluze is used to treat non-small cell lung cancer (NSCLC) that has specific EGFR mutations, including T790M-positive tumors, especially when previous treatments have failed.
Lazertinib
Generic Name/API:Lazertinib
Packaging:Two pack size : For 80 mg, 60-count bottle , For 24, 30-count bottle
Storage:Store at 15°C to 30°C
Dosage:For dosage information, please check the General Information section.
Strength:Tablets: 80 mg and 240 mg
Indication:Lazcluze is a medication used to treat certain types of leukemia, specifically chronic myeloid leukemia (CML) in adults who are resistant or intolerant to prior treatments like tyrosine kinase inhibitors. It works by inhibiting the BCR-ABL1 fusion protein, which drives the growth of leukemia cells. Its ability to address treatment-resistant cancer cases, combined with oral administration and tailored dosing, positions.
- ABOUT MEDICINE
LAZCLUZE (Lazertinib) is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test
Lazcluze’s unique selling proposition (USP) lies in its targeted mechanism of action as a highly specific tyrosine kinase inhibitor designed to effectively treat certain resistant forms of non-small cell lung cancer (NSCLC), particularly those with EGFR mutations like T790M, offering patients a precise and potentially more effective therapy with a manageable safety profile.
STRENGTH:
Tablets: 80 mg and 240 mg
DOSAGE:
The recommended dosage of LAZCLUZE is 240 mg orally once daily with or without food, given in combination with amivantamab (Rybrevant).Administer LAZCLUZE any time prior to amivantamab when given on the same day
Dose Reduction For Adverse Reactions:
| Dose At which Adverse Reaction occured | 1st Dose Reduction | 2nd Dose Reduction | 3rd Dose Reduction |
| 240mg OD(One 240 mg tablet) | 160 mg OD ( Two 80 mg tablet) | 80 mg OD(One 80 mg table) | Discontinue Medication |
Adverse Events
- Venous Thromboembolic Events:
VTE occurred in 36% of patients receiving LAZCLUZE in combination with amivantamab, including Grade 3 in 10% and Grade 4 in 0.5% of patients. On-study VTEs occurred in 1.2% of patients (n=5) while receiving anticoagulation therapy. There were two fatal cases of VTE (0.5%), 7% of patients had VTE leading to dose interruptions of LAZCLUZE, 0.5% of patients had VTE leading to dose reductions of LAZCLUZE, and 1.9% of patients permanently discontinued LAZCLUZE due to VTE.
- Interstitial Lung Disease/Pneumonitis:
ILD/pneumonitis occurred in 3.1% of patients treated with LAZCLUZE in combination with amivantamab, including Grade 3 in 1.0% and Grade 4 in 0.2% of patients. There was one fatal case (0.2%) of ILD/pneumonitis and 2.9% of patients permanently discontinued LAZCLUZE and amivantamab due to ILD/pneumonitis
- Dermatologic Adverse Reactions:
Rash occurred in 86% of patients treated with LAZCLUZE in combination with amivantamab, including Grade 3 in 26% of patients. The median time to onset of rash was 14 days (range: 1 to 556 days). Rash leading to dose reduction of LAZCLUZE occurred in 19% of patients, rash leading to dose interruption of LAZCLUZE occurred in 30% of patients, and LAZCLUZE was permanently discontinued due to rash in 1.7% of patients
- Ocular Toxicity:
Ocular toxicity occurred in 16% of patients treated with LAZCLUZE in combination with amivantamab, including Grade 3 or 4 ocular toxicity in 0.7% of patients. Promptly refer patients presenting with new or worsening eye symptoms to an ophthalmologist. Withhold, reduce the dose or permanently discontinue amivantamab and continue LAZCLUZE based on severity.
FAQ
How is Lazcluze administered?
Lazcluze is taken orally, usually once daily, as prescribed by your healthcare provider.
What are common lazertinib side effects?
Common side effects include rash, diarrhea, dry skin, cough and elevated liver enzymes. Serious side effects should be reported to your doctor immediately.
What is the mechanism of action of Lazcluze?
Lazertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that works by selectively targeting specific EGFR
mutations found in non-small cell lung cancer (NSCLC).
It specifically inhibits EGFR signaling pathways, leading to cell death (apoptosis) in cancer cells with these mutations.
What is the cost of Lazertinib (Lazcluze) tablets in India?
The cost of Lazertinib (Lazcluze) tablets in India varies as it is not always locally approved and often must be imported. Supplier availability, import duties and currency exchange rates impact the final price. For the latest cost details, contact 24/7QualityMeds at +91 9967979080.
How to buy Lazertinib tablet online in India?
To buy lazertinib (Lazcluze) tablet online in India at a genuine price, contact 24/7QualityMeds. We assist with prescription verification, facilitate legal import procedures, source from certified international suppliers and ensure safe delivery to your address.
What are the key criteria for selecting a supplier?
While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certificate and possesses a valid operating license. These credentials confirm that the suppliers adherence to International standards for the proper distribution of medicinal product
How to buy Lazertinib (Lazcluze) in Delhi?
To buy Lazertinib (Lazcluze) in Delhi, contact 24/7QualityMeds. You can legally access the medication through the Named Patient Program in Delhi by sharing your request with us.
